Rtw Investments buys $17.9 Million stake in La Jolla Pharmaceutical Company (LJPC)

La Jolla Pharmaceutical Company (LJPC) : Rtw Investments scooped up 104,818 additional shares in La Jolla Pharmaceutical Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 1,169,065 shares of La Jolla Pharmaceutical Company which is valued at $17.9 Million.La Jolla Pharmaceutical Company makes up approximately 7.20% of Rtw Investments’s portfolio.

Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in LJPC in the latest quarter, The investment management firm added 490 additional shares and now holds a total of 1,795 shares of La Jolla Pharmaceutical Company which is valued at $27,553.Blackrock Investment Management boosted its stake in LJPC in the latest quarter, The investment management firm added 1,170 additional shares and now holds a total of 48,920 shares of La Jolla Pharmaceutical Company which is valued at $750,922.P.a.w. Capital Corp boosted its stake in LJPC in the latest quarter, The investment management firm added 3,600 additional shares and now holds a total of 54,000 shares of La Jolla Pharmaceutical Company which is valued at $841,860. La Jolla Pharmaceutical Company makes up approx 0.99% of P.a.w. Capital Corp’s portfolio.Swiss National Bank boosted its stake in LJPC in the latest quarter, The investment management firm added 4,400 additional shares and now holds a total of 24,400 shares of La Jolla Pharmaceutical Company which is valued at $380,396. Russell Frank Co sold out all of its stake in LJPC during the most recent quarter. The investment firm sold 23,536 shares of LJPC which is valued $435,651.

La Jolla Pharmaceutical Company opened for trading at $15.5 and hit $15.95 on the upside on Monday, eventually ending the session at $15.91, with a gain of 3.65% or 0.56 points. The heightened volatility saw the trading volume jump to 2,22,560 shares. Company has a market cap of $290 M.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. Its four product candidates in development include LJPC-501 GCS-100 LJPC-1010 and LJPC-401. LJPC-501 is its formulation of angiotensin for the treatment of catecholamine-resistant hypotension (CRH). GCS-100 is its galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010 is its galectin-3 inhibitor. LJPC-401 is its formulation of hepcidin for the potential treatment of conditions characterized by iron overload such as hemochromatosis and beta thalassemia.

Leave a Reply

La Jolla Pharmaceutical Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on La Jolla Pharmaceutical Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.